Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer

Reference

• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–685.
   PubMed Web of Science ®Google Scholar
• Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783–791.
   PubMed Web of Science ®Google Scholar
• André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218.
   PubMed Web of Science ®Google Scholar
• Caccese M, Indraccolo S, Zagonel V, et al. PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: a concise review. Crit Rev Oncol Hematol. 2019;135:128–134.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology-Colon Cancer: version 1. 2022. http://www.nccn.org.
   Google Scholar
• Innocenti F, Ou FS, Qu X, et al. Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol. 2019;37(14):1217–1227.
   PubMed Web of Science ®Google Scholar
• Tougeron D, Sueur B, Zaanan A, et al. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: an AGEO retrospective multicenter study. Int J Cancer. 2020;147(1):285–296.
   PubMed Web of Science ®Google Scholar
• Sun D, Li H, Cao M, et al. Cancer burden in China: trends, risk factors and prevention. Cancer Biol Med. 2020;17(4):879–895.
   PubMed Web of Science ®Google Scholar
• Huang HY, Shi JF, Guo LW, et al. Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey. Chin J Cancer. 2017;36(1):41.
   PubMedGoogle Scholar
• Wu Q, Zhang P, Wang X, et al. Cost-effectiveness of capecitabine + irinotecan versus leucovorin + fluorouracil + irinotecan in the second-line treatment of metastatic colorectal cancer in China. Clin Ther. 2020;42(11):2148–2158.e2.
   PubMed Web of Science ®Google Scholar
• Levy-Piedbois C, Durand-Zaleski I, Juhel H, et al. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncol. 2000;11(2):157–161.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23(5):659–670.
   PubMed Web of Science ®Google Scholar
• Andre T, Amonkar M, Norquist JM, et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(5):665–677.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. NIH Publication No 09-5410; 2009. pp. 1–196.
   Google Scholar
• Report on Nutrition and Chronic Diseases of Chinese Residents [in Chinese]. 2020. http://www.nhc.gov.cn.
   Google Scholar
• Kashiwa M, Matsushita R. Comparative cost-effectiveness of aflibercept and ramucirumab in combination with irinotecan and fluorouracil-based therapy for the second-line treatment of metastatic colorectal cancer in Japan. Clin Ther. 2020;42(7):1361–1375.
   PubMed Web of Science ®Google Scholar
• Guoen L. Chinese pharmacoeconomic evaluation guide. Beijing: China Market Press; 2022.
   Google Scholar
• Aguiar-Ibáñez R, Hardern C, van Hees F, et al. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. J Med Econ. 2022;25(1):469–480.
   PubMed Web of Science ®Google Scholar
• Chongqing T, Sini L, Xiaohui Z, et al. Cost-effectiveness of first-line versus second-line pembrolizumab or chemotherapy in patients with microsatellite-instability-high/mismatch repair-deficient advanced colorectal cancer. Front Pharmacol. 2021;12:802942.
   PubMed Web of Science ®Google Scholar
• CMS. ASP Drug Pricing Files: Centers for Medicare and Medicaid Services. 2021. https://www.cms.gov/medicare/medicare-part-b-drug.average-sales-price/2021-asp-drug-pricing-fifiles [accessed February 2, 2021].
   Google Scholar
• Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford, UK: Oxford University Press; 1997.
   Google Scholar
• Peng Z, Hou X, Huang Y, et al. Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China. BMC Cancer. 2020;20(1):990.
   PubMed Web of Science ®Google Scholar
• WHO guide to generalized cost-effectiveness analysis. 2016. http://www. who.int/choice/cost-effectiveness/generalized/en/ [accessed October 7, 2016].
   Google Scholar
• Guan X, Li H, Xiong X, et al. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China. J Med Econ. 2021;24(1):339–344.
   PubMed Web of Science ®Google Scholar
• Yao Q, Zhang YG, Xu L. Study on the quality of life of Chinese residents from different countries’ perspective: based on the EQ-5D value set of China, Britain, Japan and Korea [in Chinese]. Chinese Health Econ. 2018;37(1):81–85.
   Google Scholar
• Li X, Li W, Hou L. A trial-based cost-effectiveness analysis of bevacizumab and chemotherapy versus chemotherapy alone for advanced nonsquamous non-small-cell lung cancer in China. Value Health Reg Issues. 2019 May;18:1–7.
   PubMedGoogle Scholar